Most Viewed Articles
Articles | Fulltext downloads | PDF downloads | Total downloads |
---|---|---|---|
Review ArticleAntibody-drug conjugate review in breast cancer: A targeted approachFull text![]() ![]() ![]() Volume 9 | Issue 3 | September-December 2024DOI: 10.25259/IJMIO_30_2024 |
12,822 | 38,905 | 51,727 |
Short CommunicationOutcome of ivermectin and doxycycline in cancer patients with COVID-19: A positive experience in BangladeshFull text![]() ![]() ![]() Volume 6 | Issue 1 | January-April 2021DOI: 10.25259/IJMIO_30_2020 |
46,775 | 3,797 | 50,572 |
Short CommunicationDriver mutations in oncogenesisFull text![]() ![]() ![]() Volume 6 | Issue 2 | May-August 2021DOI: 10.25259/IJMIO_26_2020 |
39,836 | 5,103 | 44,939 |
Review ArticleGenetic diversity and variation in chronic myeloid leukemia patients of Indian origin- Implications for treatment response and prognosisFull text![]() ![]() ![]() Volume 9 | Issue 3 | September-December 2024DOI: 10.25259/IJMIO_11_2024 |
12,289 | 32,482 | 44,771 |
Case ReportCase report – Muir–Torre syndrome – A skin-deep manifestation of underlying malignancyFull text![]() ![]() ![]() Volume 9 | Issue 3 | September-December 2024DOI: 10.25259/IJMIO_26_2024 |
12,140 | 28,916 | 41,056 |
Review ArticleMini review: Molecular pathology of personalized medicine in cancer susceptibility syndromesFull text![]() ![]() ![]() Volume 8 | Issue 3 | September-December 2023DOI: 10.25259/IJMIO_12_2023 |
28,767 | 3,283 | 32,050 |
Review ArticleEmerging strategies in cancer immunotherapy: Expanding horizons and future perspectivesFull text![]() ![]() ![]() Volume 9 | Issue 3 | September-December 2024DOI: 10.25259/IJMIO_24_2024 |
13,662 | 17,915 | 31,577 |
EditorialChallenging conventional wisdom in molecular oncology: New perspectivesFull text![]() ![]() ![]() Volume 8 | Issue 3 | September-December 2023DOI: 10.25259/IJMIO_20_2023 |
27,163 | 3,143 | 30,306 |
Case ReportBreast carcinoma disguised as systemic sclerosis: A case report of unusual paraneoplastic syndromeFull text![]() ![]() ![]() Volume 10 | Issue 1 | January-April 2025DOI: 10.25259/IJMIO_4_2024 |
9,515 | 20,599 | 30,114 |
Original ArticleOutcomes with atezolizumab and bevacizumab in hepatocellular carcinoma – Real-world data from IndiaFull text![]() ![]() ![]() Volume 8 | Issue 3 | September-December 2023DOI: 10.25259/IJMIO_15_2023 |
27,061 | 2,990 | 30,051 |
Case ReportLong-term efficacy of osimertinib in de novo exon 19 deletion with T790M in an epidermal growth factor receptor mutated lung cancer patient in IndiaFull text![]() ![]() ![]() Volume 9 | Issue 1 | January-April 2024DOI: 10.25259/IJMIO_16_2023 |
24,542 | 3,145 | 27,687 |
Review ArticleMolecular oncology and the role of artificial intelligence in advancing cancer treatmentFull text![]() ![]() ![]() Volume 8 | Issue 3 | September-December 2023DOI: 10.25259/IJMIO_17_2023 |
23,089 | 2,350 | 25,439 |
Original ArticleSpectrum of lymphomas in IndiaFull text![]() ![]() ![]() Volume 9 | Issue 1 | January-April 2024DOI: 10.25259/IJMIO_18_2023 |
19,450 | 3,049 | 22,499 |
EditorialCrucial crossroads: Making the right choice for first-line therapy in advanced urothelial cancerFull text![]() ![]() ![]() Volume 9 | Issue 1 | January-April 2024DOI: 10.25259/IJMIO_2_2024 |
18,253 | 3,807 | 22,060 |
Review ArticleUse of five-day chronomodulated prescription of palbociclib as myelopreservation drug along with Topotecan in recurrent extensive stage small cell lung carcinoma – A perspective articleFull text![]() ![]() ![]() Volume 9 | Issue 1 | January-April 2024DOI: 10.25259/IJMIO_3_2024 |
18,398 | 3,492 | 21,890 |
NewsEditorial board tribute to Dr. Amit VermaFull text![]() ![]() ![]() Volume 6 | Issue 3 | September-December 2021 |
16,695 | 4,141 | 20,836 |
Review ArticleHigh-dose nicotinamide, a histone deacetylase inhibitor (Sirtuin-1), can prevent emergence of treatment resistance in chronic myeloid leukemia – A perspectiveFull text![]() ![]() ![]() Volume 9 | Issue 1 | January-April 2024DOI: 10.25259/IJMIO_1_2024 |
17,221 | 3,199 | 20,420 |
Review ArticleCan CDK 4/6 inhibitors be used in patients with visceral crises? Deviating from conventional teachingFull text![]() ![]() ![]() Volume 7 | Issue 2 | May – August 2022DOI: 10.25259/IJMIO_8_2022 |
14,234 | 6,136 | 20,370 |
Case ReportClinical experience of total body irradiation performed on Halcyon™ for a patient diagnosed with acute myeloid leukemiaFull text![]() ![]() ![]() Volume 7 | Issue 2 | May – August 2022DOI: 10.25259/IJMIO_5_2022 |
13,270 | 6,779 | 20,049 |
Review ArticleUnderstanding immunotherapy and CAR-T-cells: A narrative reviewFull text![]() ![]() ![]() Volume 9 | Issue 1 | January-April 2024DOI: 10.25259/IJMIO_22_2023 |
17,129 | 2,742 | 19,871 |
Case ReportSquamous cell carcinoma of lung presenting as “Sunray sign” in chest radiographFull text![]() ![]() ![]() Volume 8 | Issue 3 | September-December 2023DOI: 10.25259/IJMIO_6_2023 |
15,747 | 3,056 | 18,803 |
Review ArticleIs continuous infusion of high-dose ifosfamide, a safe option? Drug reviewFull text![]() ![]() ![]() Volume 5 | Issue 2 | May-August 2020DOI: 10.25259/IJMIO_21_2019 |
13,735 | 4,747 | 18,482 |
Cardio Oncology with ACOSIbrutinib and atrial fibrillation as cardiotoxicity – A new safety warning that impacts overall survivalFull text![]() ![]() ![]() Volume 7 | Issue 2 | May – August 2022DOI: 10.25259/IJMIO_1_2022 |
12,797 | 5,369 | 18,166 |
Case ReportHyperthermic intraperitoneal chemotherapy in primary peritoneal cancer: Our experience in a young maleFull text![]() ![]() ![]() Volume 6 | Issue 3 | September-December 2021DOI: 10.25259/IJMIO_16_2021 |
14,726 | 3,111 | 17,837 |
Review ArticleSignaling pathways in pancreatic ductile adenocarcinoma and potential therapeutic targetsFull text![]() ![]() ![]() Volume 8 | Issue 3 | September-December 2023DOI: 10.25259/IJMIO_29_2022 |
14,803 | 3,003 | 17,806 |
New Drug UpdateAmlodipine-induced inhibition of NFAT-2 nuclear translocation and its utility as an additive to immune checkpoint inhibitorFull text![]() ![]() ![]() Volume 6 | Issue 3 | September-December 2021DOI: 10.25259/IJMIO_13_2021 |
14,602 | 2,932 | 17,534 |
Review ArticleCombination of PARPi and anti-PD-L1 therapies in ovarian cancerFull text![]() ![]() ![]() Volume 8 | Issue 2 | May-August 2023DOI: 10.25259/IJMIO_28_2022 |
15,123 | 2,071 | 17,194 |
Review ArticlePotential therapeutic molecular targets for better outcomes for patients with lung cancerFull text![]() ![]() ![]() Volume 8 | Issue 2 | May-August 2023DOI: 10.25259/IJMIO_27_2022 |
15,442 | 1,724 | 17,166 |
Review ArticleImmune dynamics of SARS-CoV-2 virus evolutionFull text![]() ![]() ![]() Volume 7 | Issue 1 | January-April 2022DOI: 10.25259/IJMIO_26_2021 |
11,565 | 5,569 | 17,134 |
Original ArticleIncorporation of immunohistochemistry in the assessment of survival and prognosis of endometrial cancers: Are we ready for the change?Full text![]() ![]() ![]() Volume 7 | Issue 2 | May – August 2022DOI: 10.25259/IJMIO_2_2022 |
11,924 | 5,106 | 17,030 |
Review ArticleAdvances in immunotherapy for metastatic esophageal cancerFull text![]() ![]() ![]() Volume 7 | Issue 3 | September-December 2022DOI: 10.25259/IJMIO_14_2022 |
11,187 | 5,238 | 16,425 |
Brief CommentaryBreast cancer prognostic tools: A promising Indian optionFull text![]() ![]() ![]() Volume 5 | Issue 2 | May-August 2020DOI: 10.25259/IJMIO_15_2020 |
10,614 | 5,750 | 16,364 |
Review ArticleImmuno-oncological era of breast cancer: A progressive path to better treatmentFull text![]() ![]() ![]() Volume 7 | Issue 2 | May – August 2022DOI: 10.25259/IJMIO_3_2022 |
9,886 | 6,295 | 16,181 |
Case SeriesDual driver in non-small cell lung carcinoma – therapeutic dilemmaFull text![]() ![]() ![]() Volume 7 | Issue 1 | January-April 2022DOI: 10.25259/IJMIO_22_2021 |
12,880 | 2,995 | 15,875 |
Review ArticleImmuno-oncology of differentiated thyroid cancerFull text![]() ![]() ![]() Volume 6 | Issue 2 | May-August 2021DOI: 10.25259/IJMIO_36_2020 |
11,368 | 4,385 | 15,753 |
Review ArticleA compendium of population wide DNA methylation profile for oral cancer in IndiaFull text![]() ![]() ![]() Volume 6 | Issue 2 | May-August 2021DOI: 10.25259/IJMIO_2_2021 |
10,828 | 4,733 | 15,561 |
Case ReportL1CAM expressing, ZFTA:: NCOA1 fusion-positive supratentorial ependymoma: A case reportFull text![]() ![]() ![]() Volume 8 | Issue 3 | September-December 2023DOI: 10.25259/IJMIO_11_2023 |
13,279 | 2,221 | 15,500 |
Review ArticleThe evolving role of precision medicine in the management of advanced sarcomas – A mini reviewFull text![]() ![]() ![]() Volume 6 | Issue 3 | September-December 2021DOI: 10.25259/IJMIO_6_2021 |
12,163 | 3,259 | 15,422 |
Case ReportComplete metabolic response with letrozole and palbociclib in advanced breast cancerFull text![]() ![]() ![]() Volume 4 | Issue 3 | September-December 2019DOI: 10.25259/IJMIO_2_2019 |
9,341 | 5,975 | 15,316 |
Review ArticleThe Cancer Genomic Atlas – “TO CONQUER CANCER”Full text![]() ![]() ![]() Volume 6 | Issue 2 | May-August 2021DOI: 10.25259/IJMIO_28_2020 |
10,858 | 4,435 | 15,293 |
Review ArticleEndocrine toxicity of cancer immunotherapyFull text![]() ![]() ![]() Volume 9 | Issue 2 | May-August 2024DOI: 10.25259/IJMIO_19_2024 |
13,685 | 1,408 | 15,093 |
Review ArticlePost-chemotherapy maintenance treatment by nicotinamide riboside, a poly ADP ribose polymerase 1 inhibitor, in BRCA mutated advanced ovarian cancer – A perspectiveFull text![]() ![]() ![]() Volume 6 | Issue 3 | September-December 2021DOI: 10.25259/IJMIO_12_2021 |
11,640 | 3,432 | 15,072 |
Review ArticleMolecular genetics changes in gallbladder carcinomaFull text![]() ![]() ![]() Volume 5 | Issue 2 | May-August 2020DOI: 10.25259/IJMIO_19_2019 |
9,835 | 5,214 | 15,049 |
Review ArticlePatient perspectives on living with chronic myeloid leukemia in India: Quality of life, psychosocial support, and stigmaFull text![]() ![]() ![]() Volume 9 | Issue 3 | September-December 2024DOI: 10.25259/IJMIO_17_2024 |
13,990 | 876 | 14,866 |
Case ReportUnusual presentation of an Epstein barr virus-negative extranodal natural killer/T cell lymphoma: A diagnostic dilemmaFull text![]() ![]() ![]() Volume 7 | Issue 1 | January-April 2022DOI: 10.25259/IJMIO_18_2021 |
11,722 | 3,141 | 14,863 |
Case ReportRedefining the treatment of metastatic uveal melanoma with immunotherapy – A case reportFull text![]() ![]() ![]() Volume 7 | Issue 2 | May – August 2022DOI: 10.25259/IJMIO_11_2022 |
11,371 | 3,271 | 14,642 |
EditorialNanobytesFull text![]() ![]() ![]() Volume 4 | Issue 3 | September-December 2019DOI: 10.25259/IJMIO_7_2019 |
6,836 | 7,600 | 14,436 |
Brief CommentaryERBB and FGFR2 pathway inhibition in biliary tract cancers – Dawn of a new beginningFull text![]() ![]() ![]() Volume 6 | Issue 3 | September-December 2021DOI: 10.25259/IJMIO_10_2021 |
11,008 | 3,313 | 14,321 |
Brief CommentaryBioactive lipid: A novel diagnostic approach for retinoblastoma in clinical managementFull text![]() ![]() ![]() Volume 6 | Issue 3 | September-December 2021DOI: 10.25259/IJMIO_7_2021 |
10,785 | 3,493 | 14,278 |
Conference Review6th Molecular Oncology Society Conference: Improving patient survival by molecularly targeted therapiesFull text![]() ![]() ![]() Volume 6 | Issue 3 | September-December 2021DOI: 10.25259/IJMIO_20_2021 |
11,583 | 2,622 | 14,205 |